CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...